Pro Bono, PolyTherics expand haematology alliance
The companies have extended their agreement to pursue the development of a further blood factor product, TheraPEG Factor VIIa and go ahead with the feasibility study to assess
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.